We are live on ! Find out more
SGYP

Synergy Pharmaceuticals
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

89 hedge funds and large institutions have $4.12M invested in Synergy Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 39 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

24.22% less ownership

Funds ownership: 38.82% → 14.61% (-24%)

33% less funds holding

Funds holding: 133 → 89 (-44)

41% less call options, than puts

Call options by funds: $141K | Put options by funds: $239K

59% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 39

77% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 56

95% less capital inflows, than outflows

Capital inflows: $3.26M | Capital outflows: $61M

Holders
89
Holders Change
-44
Holders Change %
-33.08%
% of All Funds
1.97%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
16
Reduced
39
Closed
56
Calls
$141​K
Puts
$239​K
Net Calls
-⁠$98​K
Net Calls Change
+$1.89​M

SGYP Hedge Fund Activity: Q4 2018 in Review

89 of the 4,507 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals (SGYP) for Q4 2018, worth a combined $4.12M — down 97% from $164M a quarter earlier.

Sellers outnumbered buyers: 56 funds closed out of SGYP and 13 opened new positions — a net loss of 43 holders — while 39 trimmed existing stakes and 16 added.

The largest buyer was Jefferies Group, adding an estimated $1M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $14M sold.

  • 89 institutional investors held Synergy Pharmaceuticals (SGYP) as of Q4 2018, down from 133 in Q3 2018.
  • Funds reported $4.12M of Synergy Pharmaceuticals stock for Q4 2018, down 97% quarter-over-quarter.
  • 13 funds opened new Synergy Pharmaceuticals positions in Q4 2018 and 56 closed out, a net change of -43 holders.
  • The largest Synergy Pharmaceuticals buyer in Q4 2018 was Jefferies Group, an estimated $1M added.
  • The largest Synergy Pharmaceuticals seller in Q4 2018 was Nantahala Capital Management, an estimated $14M sold.

Based on aggregated 13F filings for Q4 2018.